WO2015144184A8 - Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer - Google Patents
Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer Download PDFInfo
- Publication number
- WO2015144184A8 WO2015144184A8 PCT/DK2015/050069 DK2015050069W WO2015144184A8 WO 2015144184 A8 WO2015144184 A8 WO 2015144184A8 DK 2015050069 W DK2015050069 W DK 2015050069W WO 2015144184 A8 WO2015144184 A8 WO 2015144184A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- timp
- treatment
- biomarker
- colorectal cancer
- metastatic colorectal
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention concerns the provision of biomarkers, in particular, TIMP-1 and RAS as biomarkers for the selection of patients in the treatment and prognosis of cancer, such as e.g. metastatic colorectal cancer (mCRC). The present invention also provides methods of patient selection, patient prognosis and methods of treatment of patients based on TIMP-1 levels in the blood, plasma or tumor tissue and the absence or presence of mutations in RAS, in particular KRAS, who are likely to benefit from treatment with an EGFR inhibitor alone or in combination with at least one chemotherapeutic agent. The present invention also provides for a method of treatment of m CRC in patients, which have been identified by the inventive method using the biomarker TIMP-1 and KRAS, who are likely to benefit from the treatment with the EGFR inhibitor cetuximab and at least one chemotherapeutic agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400174 | 2014-03-26 | ||
DKPA201400174 | 2014-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015144184A1 WO2015144184A1 (en) | 2015-10-01 |
WO2015144184A8 true WO2015144184A8 (en) | 2015-10-29 |
Family
ID=52997162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2015/050069 WO2015144184A1 (en) | 2014-03-26 | 2015-03-26 | Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015144184A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3385395T1 (en) | 2015-08-17 | 2020-07-31 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyl transferase inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG176773A1 (en) * | 2009-06-19 | 2012-01-30 | Merck Patent Gmbh | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy |
US20130029339A1 (en) * | 2009-09-09 | 2013-01-31 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
-
2015
- 2015-03-26 WO PCT/DK2015/050069 patent/WO2015144184A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2015144184A1 (en) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122642T1 (en) | ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR THE THERAPEUTIC TREATMENT OF NON-SMALL CELL LUNG CANCER | |
MX2017014381A (en) | Therapeutic and diagnostic methods for cancer. | |
MX2017008421A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder. | |
EP3867410A4 (en) | Methods for determining treatment for cancer patients | |
WO2016196298A8 (en) | Therapeutic and diagnostic methods for cancer | |
AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
WO2014151006A3 (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
MX2016012285A (en) | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression. | |
EP3580560A4 (en) | Methods for the detection and treatment of lung cancer | |
EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
EA201692472A1 (en) | CONNECTIONS FOR THE TREATMENT OF BRAIN CANCER | |
IL273782A (en) | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same | |
MX2017014735A (en) | Pd-l1 promoter methylation in cancer. | |
MX2016001854A (en) | Compositions and method for treating complement-associated conditions. | |
AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
EP3762493A4 (en) | Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon | |
EP3796933A4 (en) | Methods for treating, preventing and detecting the prognosis of colorectal cancer | |
WO2015112705A3 (en) | Therapeutic combinations for treating cancer | |
EP3444362A3 (en) | Circulating mirnas as early detection marker and prognostic marker | |
EP3371211A4 (en) | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment | |
EP3292218A4 (en) | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer | |
MX2017014540A (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus. | |
WO2015144184A8 (en) | Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15717793 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15717793 Country of ref document: EP Kind code of ref document: A1 |